ReviewInternational journal of stroke : official journal of the International Stroke Society2024
Hyperacute ischemic stroke care-Current treatment and future directions.
Review in International journal of stroke : official journal of the International Stroke Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Treatment of Acute Ischemic Stroke with Intravenous Urokinase (TASK-UK): Protocol for a Multicenter, Prospective, Real-World Study.Neurology and therapy · 2026Article
- Observational
- Regulatory mechanisms of post-translational modifications on autophagic flux in neurons following ischemic stroke.Molecular biology reports · 2026Review
- Where are we going for the treatment in ischaemic stroke: a comprehensive study of investigator-sponsored randomised controlled trials, 1990-2024.Stroke and vascular neurology · 2026Observational
- Fibrinogenase and Direct Thrombin Inhibitor for Injection in the Treatment of Acute Ischemic Stroke.Journal of clinical medicine · 2026Article
- Post-stroke facial palsy: Prevalence, recovery patterns within the first 7 days, risk factors, and effect of hyperacute treatments.Clinical rehabilitation · 2026Article
- Application of non-invasive transcranial photobiomodulation in ischemic stroke: Mechanisms and current insights.iScience · 2026Review
- Neutrophil extracellular traps and microglia/macrophages interactions in stroke: from thromboinflammation to immunotherapy.Frontiers in immunology · 2026Review
- Tenecteplase-What Have We Learned till Now? A Narrative Review.Life (Basel, Switzerland) · 2025Review
- The changes of serum inflammatory cytokines in patients with hemiplegia after ischemic stroke and the rehabilitation effects.Journal of medical biochemistry · 2025Article
- Adjunctive Antithrombotic Medications to Acute Reperfusion Therapy: Current Evidence and Future Directions.Stroke · 2025Review
- Should we switch to tenecteplase for all ischemic strokes? Evidence and logistics.International journal of stroke : official journal of the International Stroke Society · 2025Review
- Advancements and challenges of adherence to secondary prevention medications among patients with ischemic stroke or transient ischemic attack: the healthcare quality improvement in China, 2007-2018.Therapeutic advances in neurological disorders · 2025Article
- Prediction of acupuncture efficacy in acute ischemic stroke constructing a clinical-radiomics multimodal model.Frontiers in neurology · 2025Article
- Acupuncture for post-stroke recovery: a retrospective cohort study on motor function and quality of life.Frontiers in neurologyArticle
- Geospatial optimization of Air-Mobile Stroke Unit deployment in Norway: expanding the frontiers of neurocritical care.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A decade on from the first positive thrombectomy trials, hyperacute therapies for ischemic stroke continue to rapidly advance. Effective treatments remain limited to reperfusion, although several cytoprotective approaches continue to be investigated. Intravenous fibrinolytics are now demonstrated to be beneficial up to 24 h in patients selected using perfusion imaging, but their role in patients with non-disabling symptoms appears very limited. Tenecteplase is superior to alteplase in meta-analysis of the latest trials, and adjuvant thrombolytics are an area of active investigation. Endovascular thrombectomy is beneficial in a wide range of anterior and posterior circulation large vessel occlusions up to 24 h after onset with the more distal occlusions, mild presentations, and >24 h window being the main frontiers to be tested in ongoing trials. Imaging parameters are prognostic but appear not to modify the relative treatment benefit of thrombectomy versus standard medical care. Therefore, deciding who not to treat with thrombectomy is a key clinical challenge that requires careful but rapid integration of clinical, imaging, and patient preference considerations. Systems of care to accelerate delivery of these highly effective therapies will maximize benefits for the greatest number of patients with stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.